A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.

Michael Grundman,Roger Morgan,Jason D Lickliter,Lon S Schneider,Steven DeKosky,Nicholas J Izzo,Robert Guttendorf,Michelle Higgin,Julie Pribyl,Kelsie Mozzoni,Hank Safferstein,Susan M Catalano

Alzheimer's & Dementia: Translational Research & Clinical Interventions（2019）

引用 70|浏览65

暂无评分

摘要

•CT1812 was safe and well tolerated in healthy subjects over the dose range tested.•Adverse events were generally mild and included headache and GI disturbances.•Plasma concentrations of drug increased slightly greater than dose proportionally.•CSF concentrations of drug increased with dose.•CT1812 is suitable for advancement to later stages of clinical development.

查看译文

关键词

CT1812,Alzheimer's disease (AD),Amyloid beta (Aβ),Safety,Pharmacokinetics,Clinical trial,Therapy,Single ascending dose (SAD),Multiple ascending dose (MAD),Cerebrospinal fluid (CSF)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要